Please assess the completion status of the following clinical trial:

Trial Title: Safety, Reactogenicity and Immunogenicity of Heat-stable Rotavirus Vaccine (HSRV) in Adults and Infants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1/PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~Healthy Adults:~1. Healthy adult subjects of either sex, between 18 to 45 years of age;~2. No apparent signs or symptoms of ill health;~3. Subjects properly informed about the study and having signed the informed consent form (ICF). In case of subjects' inability to read or write, having had the ICF explained to them in the presence of a study independent witness and the witness having signed the ICF;~4. Subjects' availability for the entire period of the study and reachability by study staff for post vaccination follow-up.~Healthy Infants:~1. Healthy infants of either sex, 6-8 weeks of age at the time of enrollment;~2. Born after a gestational period of 36-42 weeks with birth weight ≥ 2kg;~3. Father, mother or other legally authorized representative (guardian) properly informed about the study and having signed the informed consent form (ICF). In case of father's, mother's or other legally acceptable representative's (guardian) inability to read or write, having had the ICF explained to them in the presence of a study independent witness and the witness having signed the ICF;~4. Infant/Parents' or guardian's availability for the entire period of the study and reachability by study staff for post-vaccination follow-up.~Exclusion Criteria:~Healthy adults:~1. Known or suspected impairment of immunological function; and known immunosuppressed family members/household contacts~2. Known hypersensitivity to any component of the rotavirus vaccine;~3. Fever, with axillary temperature ≥38.1 oC (≥100.5 oF) as measured by study staff;~4. History of chronic diarrhea;~5. Clinical evidence of active gastrointestinal illness;~6. Receipt of any IM, oral, or IV corticosteroid treatment in the past 30 days;~7. Subjects' suspected to be HIV, HBV or HCV positive from the available clinical history;~8. Any subject who cannot be adequately followed for safety assessment;~9. Any conditions which, in the opinion of the investigator, might interfere with the evaluation of the study objectives;~10. Subject's inability to maintain diary card;~11. Participation in another clinical trial investigating a vaccine, drug, medical device or medicinal procedure in the 4 weeks preceding the current vaccination trial;~12. Planned participation in another clinical trial during the present trial period;~13. Subjects identified as employees of the investigator or study center, with direct involvement in the proposed study or studies under the direction of that investigator or study center as well as children, adopted or natural, of the employees or Investigator.~Healthy Infants:~1. History of congenital abdominal disorders, intussusception, or abdominal surgery;~2. Infants exhibiting signs of severe malnutrition or Known or suspected impairment of immunological function(s) in subject or his/her immediate family;~3. Developmental delay or neurological disorder;~4. Known hypersensitivity to any component of the rotavirus vaccine;~5. Prior receipt of any rotavirus vaccine;~6. Prior receipt of any dose of Diphtheria, Tetanus, Pertussis, Hepatitis B, Hib or polio virus containing vaccine(s). Birth dose of Hepatitis B and Oral Polio Vaccine is allowed to be administered to the infants as per the local immunization practices. Oral Polio Vaccines administered as a part of the National Pulse Polio Program are allowed to be administered to the infants.~7. Fever, with axillary temperature ≥38.1 oC (≥100.5 oF) as measured by study staff.~8. History of known rotavirus disease, chronic diarrhea, or failure to thrive;~9. Clinical evidence of active gastrointestinal illness including ongoing diarrheal episode (infants with GERD can participate in the study so long as this condition is well controlled with or without medication);~10. Receipt of any IM, oral, or IV corticosteroid treatment in the past 30 days (infants on inhaled steroids may be permitted to participate in the study);~11. Infants residing in a household with an immuno-compromised person (e.g., individuals with a congenital immunodeficiency, HIV infection, leukemia, lymphoma, Hodgkin's disease, multiple myeloma, generalized malignancy, chronic renal failure, nephritic syndrome, organ or bone marrow transplantation, or those receiving immunosuppressive chemotherapy including long-term systemic corticosteroids);~12. Infants already laboratory-confirmed or suspected to be HIV, HBV or HCV positive from the available clinical history or born to mothers known to be HIV, HBV or HCV positive (no specific screening for the purpose of the study would be carried out);~13. Prior receipt of a blood transfusion or blood products, including immunoglobulins, in the past 4 weeks which might interfere with the assessment of the immune response;~14. Any infants who cannot be adequately followed for safety assessment by a home visit;~15. Any conditions which, in the opinion of the investigator, might interfere with the evaluation of the study objectives;~16. Parent/s or guardian of infant unable to maintain symptom diary;~17. Participation in another clinical trial investigating a vaccine, drug, medical device or medicinal procedure in the 4 weeks preceding the current vaccination trial;~18. Planned participation in another clinical trial during the present trial period;~19. Parents/ Guardians/ Legally Authorized Representatives identified as employees of the investigator or study center, with direct involvement in the proposed study or studies under the direction of that investigator or study center as well as children, adopted or natural, of the employees or Investigator.~    -

- Gender: ALL
- Minimum Age: 6 Weeks
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Heat Stable Rotavirus (HSRV) Vaccine (Type: EXPERIMENTAL): 25 healthy adults who will be administered a single dose of test HSRV vaccine
- Placebo for Heatstable Rotavirus vaccine (Type: PLACEBO_COMPARATOR): 25 healthy adults who will be administered a single dose of placebo
- Heat Stable Rotavirus Vaccine (Type: EXPERIMENTAL): 25 healthy infants who will be administered 3-doses of test HSRV vaccine spaced at 4-week intervals
- RotaTeq (Type: ACTIVE_COMPARATOR): 25 healthy infants who will be administered 3-doses of comparator Rotateq® vaccine spaced at 4-week intervals

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete